PL2214701T3 - Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria - Google Patents

Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria

Info

Publication number
PL2214701T3
PL2214701T3 PL08843740T PL08843740T PL2214701T3 PL 2214701 T3 PL2214701 T3 PL 2214701T3 PL 08843740 T PL08843740 T PL 08843740T PL 08843740 T PL08843740 T PL 08843740T PL 2214701 T3 PL2214701 T3 PL 2214701T3
Authority
PL
Poland
Prior art keywords
eimeria
compositions
methods
immune responses
enhancing immune
Prior art date
Application number
PL08843740T
Other languages
English (en)
Inventor
Walter Bottje
Billy Hargis
Luc Berghman
Young Min Kwon
Kimberly Cole
Mandy Cox
Sherryll Layton
Saeed El-Ashram
John Barta
Guillermo Tellez
Original Assignee
The Board Of Trustees Of The University Of Arkansas
The Texas A&M University System
University Of Guelph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Arkansas, The Texas A&M University System, University Of Guelph filed Critical The Board Of Trustees Of The University Of Arkansas
Publication of PL2214701T3 publication Critical patent/PL2214701T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/455—Eimeria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL08843740T 2007-11-01 2008-11-03 Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria PL2214701T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98461207P 2007-11-01 2007-11-01

Publications (1)

Publication Number Publication Date
PL2214701T3 true PL2214701T3 (pl) 2017-01-31

Family

ID=40591796

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08843740T PL2214701T3 (pl) 2007-11-01 2008-11-03 Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
PL16175274T PL3097926T3 (pl) 2007-11-01 2008-11-03 Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16175274T PL3097926T3 (pl) 2007-11-01 2008-11-03 Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria

Country Status (14)

Country Link
US (3) US8956849B2 (pl)
EP (2) EP2214701B1 (pl)
JP (1) JP5480812B2 (pl)
CN (2) CN103893747B (pl)
AU (1) AU2008318357B2 (pl)
BR (1) BRPI0819229B1 (pl)
CA (3) CA2704422C (pl)
DK (2) DK3097926T3 (pl)
ES (2) ES2761693T3 (pl)
HU (2) HUE047164T2 (pl)
NZ (2) NZ585777A (pl)
PL (2) PL2214701T3 (pl)
PT (2) PT3097926T (pl)
WO (1) WO2009059298A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101460551B1 (ko) * 2006-09-18 2014-11-18 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역 반응을 향상시키는 조성물 및 방법
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
AU2008318615A1 (en) 2007-10-30 2009-05-07 Texas A&M University System Compositions and methods of enhancing immune responses to flagellated bacterium
CA2704422C (en) * 2007-11-01 2019-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
WO2013123412A1 (en) * 2012-02-17 2013-08-22 Children's Medical Center Corporation Conformation-stabilized trap antigens
EA030929B1 (ru) 2013-02-14 2018-10-31 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria
HK1219045A1 (zh) 2013-03-15 2017-03-24 The Board Of Trustees Of The University Of Arkansas 增强对肠道病原体免疫应答的组合物和方法
MX2017014125A (es) 2015-05-08 2018-03-01 Novozymes As Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110468069B (zh) * 2019-08-19 2020-11-06 中国水产科学研究院长江水产研究所 一种干酪乳杆菌yfi-5及其在抗鲤疱疹病毒ii型中的应用
CN113304254A (zh) * 2021-06-07 2021-08-27 吉林大学 一种微小隐孢子虫Cp15重组侵入型乳酸菌活载体疫苗

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3415145B2 (ja) * 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
KR100283541B1 (ko) 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
EP0659086B1 (en) * 1992-09-04 1998-11-11 The University of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
US5565321A (en) * 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
ES2251719T3 (es) * 1994-04-28 2006-05-01 Boehringer Ingelheim Pharmaceuticals Inc. Metodos para la proliferacion y diferenciacion de celulas b y su empleo.
EP0812206B1 (en) 1995-03-01 2002-07-10 Immunex Corporation Cd40 binding protein for stimulating an immune response
ES2214541T3 (es) 1995-06-07 2004-09-16 Immunex Corporation Muteina de cd40l.
US6713279B1 (en) * 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) * 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
AU2004199A (en) 1997-12-19 1999-07-12 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
DK1108034T3 (da) * 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Svækkede salmonella SPI2-mutanter som antigenbærere
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
AU3966200A (en) 1999-04-16 2000-11-02 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
AU1084901A (en) * 1999-10-14 2001-04-23 Martha S. Hayden-Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
ES2222152T3 (es) * 1999-12-28 2005-02-01 Akzo Nobel N.V. Vacuna con las salmonellas que no inducen anticuerpos que reaccionan con la flagelina o los flagelos.
US7371392B2 (en) * 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
DE60112413T2 (de) * 2000-03-17 2006-06-01 Pharmacia & Upjohn Co. Llc, Kalamazoo Ssa inaktivierte salmonella impfstoffe
GB0015426D0 (en) * 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
US20030165538A1 (en) 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002036769A2 (en) 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2447593C (en) 2001-05-15 2014-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
CN100348608C (zh) * 2001-07-06 2007-11-14 Abic特瓦生物实验室有限公司 编码重组的来源于巨型艾美球虫子孢子/裂殖子的250kDa抗原的核酸,和它们的应用
ZA200400479B (en) 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US7378089B2 (en) 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
US7238499B2 (en) * 2001-12-21 2007-07-03 Immunex Corporation Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
WO2003067991A1 (en) * 2002-02-13 2003-08-21 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
EP1499191B1 (en) * 2002-04-15 2012-05-09 Washington University in St. Louis Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) * 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
EP1720905A2 (en) 2003-12-11 2006-11-15 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
EP1809737B9 (en) * 2004-10-07 2011-10-05 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
BRPI0616978A2 (pt) * 2005-10-07 2011-07-05 Proyecto Biomedicina Cima Sl combinação imuno-estimulante para a profilaxia e tratamento de hepatite c, sua utilização, composição farmacêutica que a contém, kit para sua administração, método para produzir uma resposta imune e vacina contra o vìrus da hepatite c
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
DE102005054643B3 (de) 2005-11-10 2007-02-15 Assa Abloy Sicherheitstechnik Gmbh Schließzylinder
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007106073A2 (en) * 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
FR2898905B1 (fr) * 2006-03-24 2008-05-09 Rhodia Recherches & Tech Composition polyisocyanate a proprietes anti-chocs ameliorees
WO2008027394A2 (en) * 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
KR101460551B1 (ko) 2006-09-18 2014-11-18 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역 반응을 향상시키는 조성물 및 방법
EP2139913A4 (en) * 2007-03-08 2011-09-21 Mayo Foundation INTRODUCTION OF IMMUNE-MEDIUM TUMOR CELL DEOD
CN101024076B (zh) * 2007-03-29 2010-08-18 中国农业大学 球虫的新用途
EP3321277B1 (en) * 2007-07-10 2019-09-18 Apogenix AG Tnf superfamily collectin fusion proteins
AU2008318615A1 (en) 2007-10-30 2009-05-07 Texas A&M University System Compositions and methods of enhancing immune responses to flagellated bacterium
CA2704422C (en) * 2007-11-01 2019-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
HUE025236T2 (en) * 2008-07-21 2016-03-29 Apogenix Gmbh TNFSF single chain molecules
US8316310B2 (en) 2008-08-05 2012-11-20 International Business Machines Corporation System and method for human identification proof for use in virtual environments
EP2184229B1 (en) * 2008-11-11 2012-10-17 AGUSTAWESTLAND S.p.A. Helicopter rotor
US20100150958A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
DK2525817T3 (en) * 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
HRP20201513T1 (hr) * 2011-10-11 2020-12-11 Viela Bio, Inc. Cd40l-specifični tn3-izvedeni skeleti i postupci njihove uporabe
WO2014043215A1 (en) * 2012-09-11 2014-03-20 The Texas A&M University System Bi-specifc diabodies for masking and targeting vaccines
JP6284537B2 (ja) * 2012-10-29 2018-02-28 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 新規粘膜アジュバントおよびデリバリーシステム
EA030929B1 (ru) * 2013-02-14 2018-10-31 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria
HK1219045A1 (zh) * 2013-03-15 2017-03-24 The Board Of Trustees Of The University Of Arkansas 增强对肠道病原体免疫应答的组合物和方法
JP2017523136A (ja) * 2014-06-05 2017-08-17 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 抗体誘導ワクチン及び迅速な成熟免疫応答の発生のための使用方法
US20160090603A1 (en) * 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
CN109715207B (zh) * 2016-03-29 2023-03-31 南加利福尼亚大学 靶向癌症的嵌合抗原受体
KR20220028143A (ko) * 2016-05-27 2022-03-08 애브비 바이오테라퓨틱스 인크. 항-cd40 항체 및 이의 용도
CN109803977B (zh) * 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法

Also Published As

Publication number Publication date
US20180333474A1 (en) 2018-11-22
PT2214701T (pt) 2016-11-02
BRPI0819229A2 (pt) 2015-05-05
US10016493B2 (en) 2018-07-10
HK1146575A1 (zh) 2011-06-24
CN101969990A (zh) 2011-02-09
CA3156538A1 (en) 2009-05-07
NZ601880A (en) 2013-12-20
JP2011503003A (ja) 2011-01-27
JP5480812B2 (ja) 2014-04-23
AU2008318357A1 (en) 2009-05-07
US8956849B2 (en) 2015-02-17
ES2761693T3 (es) 2020-05-20
PT3097926T (pt) 2020-01-08
EP2214701B1 (en) 2016-08-03
NZ585777A (en) 2012-09-28
CA3156538C (en) 2023-12-12
AU2008318357B2 (en) 2015-01-22
CN103893747B (zh) 2016-01-06
EP3097926A1 (en) 2016-11-30
CN101969990B (zh) 2014-07-09
HUE030655T2 (en) 2017-05-29
CA2704422C (en) 2019-09-24
CA3051748A1 (en) 2009-05-07
WO2009059298A3 (en) 2009-09-24
US20150216954A1 (en) 2015-08-06
DK3097926T3 (da) 2019-12-16
CN103893747A (zh) 2014-07-02
WO2009059298A2 (en) 2009-05-07
BRPI0819229B1 (pt) 2019-01-22
EP3097926B1 (en) 2019-10-02
AU2008318357A2 (en) 2010-06-24
PL3097926T3 (pl) 2020-04-30
CA3051748C (en) 2022-07-12
EP2214701A2 (en) 2010-08-11
CA2704422A1 (en) 2009-05-07
US20110111015A1 (en) 2011-05-12
WO2009059298A8 (en) 2010-08-05
DK2214701T3 (en) 2016-12-12
HUE047164T2 (hu) 2020-04-28
ES2599905T3 (es) 2017-02-06
EP2214701A4 (en) 2011-06-01
US10842858B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
HUE047164T2 (hu) Kompozíciók és eljárások eimeria elleni immunválasz fokozására
EP2066339A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING IMMUNE RESPONSES
EP2334185A4 (en) COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
IL208946A0 (en) Immunomodulating compositions and methods of use thereof
SI2640842T1 (sl) Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
ZA201101641B (en) Use of mtor inhibitors to enhance t cell immune responses
IL220715A0 (en) Nutritive compositions and methods of using same
IL201364A0 (en) Gas-effusing compositions and methods of making and using same
ZA201003964B (en) Compositions for and methods of enhancing the immune response to antigens
GB0812890D0 (en) Compositions and methods of making compositions
IL247929B (en) Stable compositions of 595–sns and methods for their preparation
GB0801479D0 (en) Improvements to methods of in field analysis
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
PL2328402T3 (pl) Sposoby i kompozycje do wydłużenia okresu przechowywania owoców
ZA200908300B (en) Natural honey-containing compositions and method of preparation
ZA201100114B (en) Nutritive compositions and methods of using same
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
SI2401400T1 (sl) Metode in sestavki za ocenjevanje kroničnih avtoimunskih bolezni
AU2009900926A0 (en) Compositions and methods for enhancing immune responses